

ESMO Preceptorship Programme

Neuroendocrine neoplasms – Prague – 28-29 April 2017

European Society for Medical Oncology

Portuguese Institute of Oncology of Coimbra - Clinical Cancer Center (OECI) Coimbra, Portugal Jorge Ferreira Cruz, Medical Oncology Resident

Metastatic Typical Bronchial Neuroendocrine Tumor



- 65 years-old woman
- Not known comorbidities
- Retired, worked in textile industry
- ECOG PS 0
- August / 2011
 - Presented an asymptomatic solitary pulmonary nodule on routine chest radiograph
 - In an evaluation by internal medicine, she was diagnosed with typical bronchial neuroendocrine tumor by transthoracic needle biopsy
 - Immunohistochemistry: Synaptofisin + ; NSE + ; CgA + ; TTF1 Inconclusive.




Fig. 1 – Chest radiograph





Fig. 2 – CT scan: 69mm mass in the right middle lobe



- November / 2011 Referred to our institution
 - Chest CT Scan and 99mTc-HYNIC-TOC Scintigraphy: negative for metastatic disease




- February / 2012
 - ECOG PS 0; Asymptomatic;
 - Middle right lobectomy Histology: <u>Typical low-grade bronchial NET. Scare</u> <u>mitotic figures (<2 per 10 HPF), without necrosis</u> – pT2pN0
 - MDT Decision: Posttreatment surveillance Regular follow-up



• November / 2013

 Chest CT Scan: Multiple nodular right pleural thickening; right pleural effusion; hilar and mediastinal adenopathy; D2 and D10 vertebral lesions; splenic and liver envolvement (multiple liver metastasis)



ESMO PRECEPTORSHIP PROGRAM

European Society for Medical Oncology

OD SCIENCE

ST PRACTICE

• December / 2013

- 68-Ga DOTATATE PET/CT: positive in pleuropulmonary, liver and bone lesions




Fig. 8, 9, 10 – 68-Ga DOTATATE PET/CT



- January / 2014
 - ECOG PS 0-1; Slight upper back pain; diarrhea;
 - Disease recurrence;
 - MDT Decision: Proposed treatment Octreotide LAR (30mg) + Palliative chemotherapy with platinum-based regimen (Cisplatin plus Etoposide).

- June / 2014
 - **Response assessment:** Cisplatin plus Etoposide x 6 cycles; Octreotide x 5 cycles
 - ECOG PS 1; Alopecia, GII nausea; No other major toxicities;
 - Chest-abdomen CT Scan: Stable disease;
 - Proposed treatment: Maintenance treatment with Octerotide



- February / 2015
 - Recurrent episodes of bronchospasm \rightarrow emergency care
 - ECOG PS 1-2
 - − → Clinical progression(?)
- April / 2015
 - 68-Ga DOTATATE PET/CT: **Disease progression**




Fig. 11 – 68-Ga DOTATATE PET/CT


- Stopped octreotide after 16 cycles





- May / 2015
 - ECOG PS 1; Upper back pain; Mild respiratory symptoms
 - MDT Decision: Peptide receptor radioligand therapy (PRRT)
 - 26/07/2015 until 18/12/2015
 - No major toxicities

- April / 2016 Present
 - 68-Ga DOTATATE PET/CT: Partial Response \rightarrow Regular follow-up;

- Last observation in February/2017;
- ECOG PS 0; Asymptomatic.









ESMO PRECEPTORSHIP PROGRAM

European Society for Medical Oncology

• Next?...





ESMO PRECEPTORSHIP PROGRAM

European Society for Medical Oncology





ESMO PRECEPTORSHIP PROGRAM

European Society for Medical Oncology